understanding the modulatory role of the membrane environment on the organization and dynamics of GPCRs in diseases

Modulation of GPCR receptors common to gut inflammatory diseases and neuronal disorders, Alzheimer's and Parkinson's diseases as druggable targets through Withania somnifera bioactives: an in silico study

phases of clinical development, and across multiple therapeutic areas, including Oncology, Infectious Diseases

determines the potential of a GPCR for arrestin-biased agonism The roles of RGS proteins in cardiometabolic disease Receptor Responses to Sequential Injections of Pure and Mixed Sweeteners GPCRs involved in metabolic diseases

The mGlu5 receptor is a promising target for the treatment of psychiatric and neurodegenerative diseases

fluorescent GPCR ligands "G-protein coupled receptors (GPCRs) have been largely targeted in a wide range of diseases

protein-coupled receptors (aGPCRs) are keys of many physiological events and attractive targets for various diseases

plant-like” behavior in important human cell regulator, opening up a new drug target for cancer, other diseases Neuroscience Diverse signaling mechanisms and heterogeneity of astrocyte reactivity in Alzheimer's disease

/3 APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease transport by CCHCR1 via direct interaction Industry News Novartis Lutathera® significantly reduced risk of disease

Sosei Heptares’ world-leading StaR® (stabilized receptor) platform to generate novel antibody leads to disease-relevant

including expensive cost of reagents, optimizing sensor expression levels and adapting these systems to disease-relevant the development of the BERKY and the ONE-GO biosensors, designed to facilitate their application in disease

September 2022 "G-protein-coupled receptors (GPCRs) are involved in a wide array of physiological and disease high PAR4-driven tumors, and is abundantly expressed in large tumors, whereas very little to almost none

September 2022 "G protein‐coupled receptors (GPCRs) are valuable therapeutic targets for many diseases

the C5aR1, which has received enormous attention for its role in both acute and chronic inflammatory diseases

The mGlu5 receptor is a promising target for the treatment of psychiatric and neurodegenerative diseases

receptor type 9 (CCR9) antagonist and previous phase III clinical candidate for the treatment of Crohn's disease

free fatty acid receptors (FFARs), now regarded as targets for therapeutic intervention for metabolic diseases such as liver disease, obesity and diabetes (Secor et al. 2021; Wold and Zhou 2018).

chronic clinical syndrome characterized by the reduction in cardiac function and still remains the disease

Receptors: Insights into Potential Therapeutic Opportunities for COVID-19, Heart Failure, and Alzheimer's Disease Reviews, GPCRs, and more Cell-trafficking impairment in disease-associated LPA6 missense mutants and

to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics for Difficult to Treat Diseases

Potential Implications for Idiopathic Pulmonary Fibrosis "Idiopathic pulmonary fibrosis (IPF) is a disease

focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases

Moreover, the dysregulation of TLR4 contributes to numerous diseases, which highlights the importance

optic nerve crush in mice "Glaucoma is an optic neuropathy and is currently one of the most common diseases

Immunology Germinal Center-Related G Protein-Coupled Receptors in Antibody-Mediated Autoimmune Skin Diseases quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson's disease

using next-generation GRABNE sensors Reviews, GPCRs, and more Advances in GPCRs: Structure, Mechanisms, Disease Therapeutics Secures VLAIO Grant Supporting Drug Discovery & Development In Endocrine And Metabolic Diseases

patient outcomes "Triple-negative breast cancer (TNBC) is a particularly aggressive and heterogeneous disease

Cells: Implications for Targeted Therapy "Pancreatic ductal adenocarcinoma (PDAC) remains an aggressive disease